相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study
Samy Babai et al.
DRUG SAFETY (2020)
Management of Immunotherapy-Related Toxicities. Version 1.2019
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma
Shelley Ji Eun Hwang et al.
MELANOMA RESEARCH (2019)
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy
Daniel Johnson et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Fiamma Berner et al.
JAMA ONCOLOGY (2019)
Treatment Outcomes of Immune-Related Cutaneous Adverse Events
Gregory S. Phillips et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab
Yutaka Kuwatsuka et al.
JOURNAL OF DERMATOLOGY (2018)
Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma
N. R. Adler et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2018)
A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors
Adriana T. Lopez et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2018)
Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy
Leo L. Wang et al.
JAMA DERMATOLOGY (2018)
Stevens-Johnson syndrome during nivolumab treatment of NSCLC
M. Salati et al.
ANNALS OF ONCOLOGY (2018)
Dermatologic Reactions to Immune Checkpoint Inhibitors Skin Toxicities and Immunotherapy
Vincent Sibaud
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2018)
Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy
Karina L. Vivar et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2017)
Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity
Ryota Tanaka et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2017)
Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report
Takeshi Uenami et al.
LUNG CANCER (2017)
Aprepitant for refractory nivolumab-induced pruritus
Jiro Ito et al.
LUNG CANCER (2017)
Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome
Sayeef Mirza et al.
MELANOMA RESEARCH (2017)
Nivolumab Therapy for Treatment-Related Vitiligo in a Patient With Relapsed Metastatic Melanoma
Yasuhiro Nakamura et al.
JAMA DERMATOLOGY (2017)
Anti-PD1/PDL1 induced psoriasis
Dimitra Voudouri et al.
CURRENT PROBLEMS IN CANCER (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
V. R. Belum et al.
EUROPEAN JOURNAL OF CANCER (2016)
Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy
Kurt B. Schaberg et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2016)
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
Camille Hua et al.
JAMA DERMATOLOGY (2016)
PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer
John Dulos et al.
JOURNAL OF IMMUNOTHERAPY (2012)
分享论文
